Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
Product Description
ATGAM is indicated for the treatment of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation. When administered with a regimen of supportive care, ATGAM may induce partial or complete hematologic remission.